Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Summary

This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.

Timeline

Start

2017-04-14

Primary completion

2018-11-12

Completion

2018-11-12

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of accrual”

Drugs

Indications